BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, Codding CE, Carlson TH, Delles C, Lee JS. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2013;Epub ahead of print. [PMID: 24368514 DOI: 10.1136/annrheumdis-2013-204345] [Cited by in Crossref: 159] [Cited by in F6Publishing: 163] [Article Influence: 19.9] [Reference Citation Analysis]
Number Citing Articles
1 Mackey RH, Kuller LH, Moreland LW. Inflammatory joint diseases and atherosclerosis: time to look beyond the 'lipid paradox'. Curr Opin Lipidol 2019;30:342-9. [PMID: 31145122 DOI: 10.1097/MOL.0000000000000620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
2 Bacchiega BC, Bacchiega AB, Usnayo MJ, Bedirian R, Singh G, Pinheiro GD. Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study. J Am Heart Assoc 2017;6:e005038. [PMID: 28288972 DOI: 10.1161/JAHA.116.005038] [Cited by in Crossref: 64] [Cited by in F6Publishing: 38] [Article Influence: 16.0] [Reference Citation Analysis]
3 Chistiakov DA, Melnichenko AA, Grechko AV, Myasoedova VA, Orekhov AN. Potential of anti-inflammatory agents for treatment of atherosclerosis. Exp Mol Pathol 2018;104:114-24. [PMID: 29378168 DOI: 10.1016/j.yexmp.2018.01.008] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 14.0] [Reference Citation Analysis]
4 Ruiz-Limón P, Ortega R, Arias de la Rosa I, Abalos-Aguilera MDC, Perez-Sanchez C, Jimenez-Gomez Y, Peralbo-Santaella E, Font P, Ruiz-Vilches D, Ferrin G, Collantes-Estevez E, Escudero-Contreras A, López-Pedrera C, Barbarroja N. Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. Transl Res 2017;183:87-103. [PMID: 28027930 DOI: 10.1016/j.trsl.2016.12.003] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
5 Bohr AH, Pedersen FK, Nielsen CH, Müller KG. Lipoprotein cholesterol fractions are related to markers of inflammation in children and adolescents with juvenile idiopathic arthritis: a cross sectional study. Pediatr Rheumatol Online J 2016;14:61. [PMID: 27835952 DOI: 10.1186/s12969-016-0120-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
6 Yalta T, Yalta K. Systemic Inflammation and Arrhythmogenesis: A Review of Mechanistic and Clinical Perspectives. Angiology 2018;69:288-96. [DOI: 10.1177/0003319717709380] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
7 Jones SA, Takeuchi T, Aletaha D, Smolen J, Choy EH, Mcinnes I. Interleukin 6: The biology behind the therapy. Considerations Med 2019;2:2-6. [DOI: 10.1136/conmed-2018-000005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
8 Kottoor SJ, Arora RR. The Utility of Anti-Inflammatory Agents in Cardiovascular Disease: A Novel Perspective on the Treatment of Atherosclerosis. J Cardiovasc Pharmacol Ther 2018;23:483-93. [PMID: 29783850 DOI: 10.1177/1074248418778548] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
9 Blum A, Adawi M. Rheumatoid arthritis (RA) and cardiovascular disease. Autoimmun Rev 2019;18:679-90. [PMID: 31059840 DOI: 10.1016/j.autrev.2019.05.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 15.5] [Reference Citation Analysis]
10 Braun J, Krüger K, Manger B, Schneider M, Specker C, Trappe HJ. Cardiovascular Comorbidity in Inflammatory Rheumatological Conditions. Dtsch Arztebl Int 2017;114:197-203. [PMID: 28407841 DOI: 10.3238/arztebl.2017.0197] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
11 Ferguson LD, Siebert S, McInnes IB, Sattar N. Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions. Nat Rev Rheumatol 2019;15:461-74. [PMID: 31292564 DOI: 10.1038/s41584-019-0256-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 16.5] [Reference Citation Analysis]
12 Shen J, Shang Q, Tam L. Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis. Translational Research 2016;167:138-51. [DOI: 10.1016/j.trsl.2015.05.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
13 Titanji B, Gavegnano C, Hsue P, Schinazi R, Marconi VC. Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection. J Am Heart Assoc 2020;9:e014873. [PMID: 31973607 DOI: 10.1161/JAHA.119.014873] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
14 Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Circ Res 2016;118:145-56. [PMID: 26837745 DOI: 10.1161/CIRCRESAHA.115.306656] [Cited by in Crossref: 394] [Cited by in F6Publishing: 188] [Article Influence: 78.8] [Reference Citation Analysis]
15 Prasad M, Hermann J, Gabriel SE, Weyand CM, Mulvagh S, Mankad R, Oh JK, Matteson EL, Lerman A. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol 2015;12:168-76. [PMID: 25533796 DOI: 10.1038/nrcardio.2014.206] [Cited by in Crossref: 100] [Cited by in F6Publishing: 65] [Article Influence: 14.3] [Reference Citation Analysis]
16 Charles-schoeman C, Wicker P, Gonzalez-gay MA, Boy M, Zuckerman A, Soma K, Geier J, Kwok K, Riese R. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Seminars in Arthritis and Rheumatism 2016;46:261-71. [DOI: 10.1016/j.semarthrit.2016.05.014] [Cited by in Crossref: 76] [Cited by in F6Publishing: 65] [Article Influence: 15.2] [Reference Citation Analysis]
17 Currie G, Delles C. Precision Medicine and Personalized Medicine in Cardiovascular Disease. Adv Exp Med Biol 2018;1065:589-605. [PMID: 30051409 DOI: 10.1007/978-3-319-77932-4_36] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
18 Giles JT. Cardiovascular disease in rheumatoid arthritis: Current perspectives on assessing and mitigating risk in clinical practice. Best Practice & Research Clinical Rheumatology 2015;29:597-613. [DOI: 10.1016/j.berh.2015.09.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
19 Liao KP. Cardiovascular disease in patients with rheumatoid arthritis. Trends Cardiovasc Med 2017;27:136-40. [PMID: 27612551 DOI: 10.1016/j.tcm.2016.07.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 7.8] [Reference Citation Analysis]
20 Taylor PC, Atzeni F, Balsa A, Gossec L, Müller-Ladner U, Pope J. The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. J Clin Med 2021;10:509. [PMID: 33535498 DOI: 10.3390/jcm10030509] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Imamura H, Momohara S, Yano K, Sakuma Y, Nakayama M, Tobimatsu H, Ikari K. Tocilizumab treatment in patients with rheumatoid arthritis is associated with reduced fibrinogen levels and increased blood loss after total knee arthroplasty. Mod Rheumatol 2018;28:976-80. [PMID: 29325462 DOI: 10.1080/14397595.2018.1428041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Wang L, Zhang Y, Zhang S. Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy. Front Cardiovasc Med 2020;7:78. [PMID: 32426374 DOI: 10.3389/fcvm.2020.00078] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
23 Nurmohamed M, Choy E, Lula S, Kola B, DeMasi R, Accossato P. The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review. Drug Saf 2018;41:473-88. [PMID: 29318514 DOI: 10.1007/s40264-017-0628-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
24 Otsuka Y, Kiyohara C, Kashiwado Y, Sawabe T, Nagano S, Kimoto Y, Ayano M, Mitoma H, Akahoshi M, Arinobu Y, Niiro H, Akashi K, Horiuchi T. Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study. PLoS One 2018;13:e0196368. [PMID: 29694426 DOI: 10.1371/journal.pone.0196368] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
25 McGrath CM, Young SP. Lipid and Metabolic Changes in Rheumatoid Arthritis. Curr Rheumatol Rep 2015;17:57. [PMID: 26210510 DOI: 10.1007/s11926-015-0534-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
26 Schulte DM, Paulsen K, Türk K, Brandt B, Freitag-Wolf S, Hagen I, Zeuner R, Schröder JO, Lieb W, Franke A, Nikolaus S, Mrowietz U, Gerdes S, Schreiber S, Laudes M. Small dense LDL cholesterol in human subjects with different chronic inflammatory diseases. Nutr Metab Cardiovasc Dis 2018;28:1100-5. [PMID: 30143407 DOI: 10.1016/j.numecd.2018.06.022] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
27 Borrelli MJ, Youssef A, Boffa MB, Koschinsky ML. New Frontiers in Lp(a)-Targeted Therapies. Trends Pharmacol Sci 2019;40:212-25. [PMID: 30732864 DOI: 10.1016/j.tips.2019.01.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
28 Giles JT, Sattar N, Gabriel S, Ridker PM, Gay S, Warne C, Musselman D, Brockwell L, Shittu E, Klearman M, Fleming TR. Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis Rheumatol 2019;72:31-40. [DOI: 10.1002/art.41095] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 24.0] [Reference Citation Analysis]
29 Charles-Schoeman C, Yin Lee Y, Shahbazian A, Wang X, Elashoff D, Curtis JR, Navarro-Millán I, Yang S, Chen L, Cofield SS, Moreland LW, Paulus H, O'Dell J, Bathon J, Louis Bridges S Jr, Reddy ST. Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial. Arthritis Rheumatol 2017;69:46-57. [PMID: 27483410 DOI: 10.1002/art.39833] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
30 England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ 2018;361:k1036. [PMID: 29685876 DOI: 10.1136/bmj.k1036] [Cited by in Crossref: 99] [Cited by in F6Publishing: 73] [Article Influence: 33.0] [Reference Citation Analysis]
31 McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 2017;389:2328-37. [PMID: 28612747 DOI: 10.1016/S0140-6736(17)31472-1] [Cited by in Crossref: 440] [Cited by in F6Publishing: 199] [Article Influence: 110.0] [Reference Citation Analysis]
32 García-Gómez C, Martín-Martínez MA, Castañeda S, Sanchez-Alonso F, Uriarte-Ecenarro M, González-Juanatey C, Romera-Baures M, Santos-Rey J, Pinto-Tasende JA, Quesada-Masachs E, Tornero-Molina J, Martínez-González O, Cobo-Ibáñez T, Chamizo-Carmona E, Manrique-Arija S, Fábregas-Canales D, Díaz-González F, Llorca J, González-Gay MA; CARMA Project Collaborative Group. Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project. J Clin Lipidol 2017;11:749-756.e3. [PMID: 28476652 DOI: 10.1016/j.jacl.2017.02.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
33 Robertson J, Porter D, Sattar N, Packard CJ, Caslake M, McInnes I, McCarey D. Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. Ann Rheum Dis 2017;76:1949-52. [PMID: 28916714 DOI: 10.1136/annrheumdis-2017-211708] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 9.0] [Reference Citation Analysis]
34 Kelly E, Hemphill L. Lipoprotein(a): A Lipoprotein Whose Time Has Come. Curr Treat Options Cardio Med 2017;19. [DOI: 10.1007/s11936-017-0549-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
35 Yamabe T, Ohmura SI, Uehara K, Naniwa T. Macrophage activation syndrome in patients with adult-onset Still's disease under tocilizumab treatment: A single-center observational study. Mod Rheumatol 2021;:1-8. [PMID: 33719871 DOI: 10.1080/14397595.2021.1899565] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Desjardins MP, Sidibé A, Fortier C, Mac-Way F, Marquis K, De Serres S, Larivière R, Agharazii M. Association of interleukin-6 with aortic stiffness in end-stage renal disease. J Am Soc Hypertens 2018;12:5-13. [PMID: 29170076 DOI: 10.1016/j.jash.2017.09.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
37 Calabrese LH, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol 2014;10:720-7. [PMID: 25136784 DOI: 10.1038/nrrheum.2014.127] [Cited by in Crossref: 193] [Cited by in F6Publishing: 165] [Article Influence: 27.6] [Reference Citation Analysis]
38 Jin S, Sun S, Ling H, Ma J, Zhang X, Xie Z, Zhan N, Zheng W, Li M, Qin Y, Zhao H, Chen Y, Yang X, Wang J. Protectin DX restores Treg/Th17 cell balance in rheumatoid arthritis by inhibiting NLRP3 inflammasome via miR-20a. Cell Death Dis 2021;12:280. [PMID: 33723242 DOI: 10.1038/s41419-021-03562-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
39 Ridker PM, Rane M. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. Circ Res 2021;128:1728-46. [PMID: 33998272 DOI: 10.1161/CIRCRESAHA.121.319077] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Wang Y, Golden JB, Fritz Y, Zhang X, Diaconu D, Camhi MI, Gao H, Dawes SM, Xing X, Ganesh SK, Gudjonsson JE, Simon DI, McCormick TS, Ward NL. Interleukin 6 regulates psoriasiform inflammation-associated thrombosis. JCI Insight 2016;1:e89384. [PMID: 27942589 DOI: 10.1172/jci.insight.89384] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
41 Virone A, Bastard JP, Fellahi S, Capeau J, Rouanet S, Sibilia J, Ravaud P, Berenbaum F, Gottenberg JE, Sellam J. Comparative effect of tumour necrosis factor inhibitors vs other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis. RMD Open. 2019;5:e000897. [PMID: 31413865 DOI: 10.1136/rmdopen-2019-000897] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
42 Connelly MA, Shalaurova I, Otvos JD. High-density lipoprotein and inflammation in cardiovascular disease. Translational Research 2016;173:7-18. [DOI: 10.1016/j.trsl.2016.01.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
43 Mócsai A, Kovács L, Gergely P. What is the future of targeted therapy in rheumatology: biologics or small molecules? BMC Med 2014;12:43. [PMID: 24620738 DOI: 10.1186/1741-7015-12-43] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 10.0] [Reference Citation Analysis]
44 Hansildaar R, Vedder D, Baniaamam M, Tausche AK, Gerritsen M, Nurmohamed MT. Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet Rheumatol 2021;3:e58-70. [PMID: 32904897 DOI: 10.1016/S2665-9913(20)30221-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 24.0] [Reference Citation Analysis]
45 Halacoglu J, Shea LA. Cardiovascular Risk Assessment and Therapeutic Implications in Rheumatoid Arthritis. J Cardiovasc Transl Res 2020;13:878-90. [PMID: 32080804 DOI: 10.1007/s12265-020-09964-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
46 Khambhati J, Engels M, Allard-Ratick M, Sandesara PB, Quyyumi AA, Sperling L. Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities. Atherosclerosis 2018;276:1-9. [PMID: 30006321 DOI: 10.1016/j.atherosclerosis.2018.07.007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
47 Ellis KL, Watts GF. Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic? Cardiol Clin 2018;36:287-98. [PMID: 29609758 DOI: 10.1016/j.ccl.2017.12.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
48 Robinson MB, Deshpande DA, Chou J, Cui W, Smith S, Langefeld C, Hastie AT, Bleecker ER, Hawkins GA. IL-6 trans-signaling increases expression of airways disease genes in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2015;309:L129-38. [PMID: 26001777 DOI: 10.1152/ajplung.00288.2014] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
49 Mohinta S, Kannan AK, Gowda K, Amin SG, Perdew GH, August A. Differential regulation of Th17 and T regulatory cell differentiation by aryl hydrocarbon receptor dependent xenobiotic response element dependent and independent pathways. Toxicol Sci 2015;145:233-43. [PMID: 25716673 DOI: 10.1093/toxsci/kfv046] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
50 Ueland T, Kleveland O, Michelsen AE, Wiseth R, Damås JK, Holven KB, Aukrust P, Gullestad L, Yndestad A, Halvorsen B. Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction. Int J Cardiol 2019;274:348-50. [PMID: 29961573 DOI: 10.1016/j.ijcard.2018.06.093] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
51 Trott DW, Fadel PJ. Inflammation as a mediator of arterial ageing. Exp Physiol 2019;104:1455-71. [PMID: 31325339 DOI: 10.1113/EP087499] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
52 Erlandsson MC, Töyrä Silfverswärd S, Nadali M, Turkkila M, Svensson MND, Jonsson IM, Andersson KME, Bokarewa MI. IGF-1R signalling contributes to IL-6 production and T cell dependent inflammation in rheumatoid arthritis. Biochim Biophys Acta Mol Basis Dis 2017;1863:2158-70. [PMID: 28583713 DOI: 10.1016/j.bbadis.2017.06.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
53 Han CY, Tang C, Guevara ME, Wei H, Wietecha T, Shao B, Subramanian S, Omer M, Wang S, O'Brien KD, Marcovina SM, Wight TN, Vaisar T, de Beer MC, de Beer FC, Osborne WR, Elkon KB, Chait A. Serum amyloid A impairs the antiinflammatory properties of HDL. J Clin Invest 2016;126:266-81. [PMID: 26642365 DOI: 10.1172/JCI83475] [Cited by in Crossref: 72] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
54 Choi IA, Sagawa A, Lee EY, Lee EB, Song YW. Tocilizumab Increases Body Weight and Serum Adipokine Levels in Patients with Rheumatoid Arthritis Independently of Their Treatment Response: a Retrospective Cohort Study. J Korean Med Sci 2020;35:e155. [PMID: 32508063 DOI: 10.3346/jkms.2020.35.e155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
55 Castagné B, Viprey M, Martin J, Schott AM, Cucherat M, Soubrier M. Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis. PLoS One 2019;14:e0220178. [PMID: 31369575 DOI: 10.1371/journal.pone.0220178] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 13.5] [Reference Citation Analysis]
56 Catapano AL, Pirillo A, Norata GD. Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials. Br J Pharmacol 2017;174:3973-85. [PMID: 28369752 DOI: 10.1111/bph.13805] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 16.8] [Reference Citation Analysis]
57 McMahon M, Skaggs B, Grossman J, Wong WK, Sahakian L, Chen W, Hahn B. Comparison of PREDICTS atherosclerosis biomarker changes after initiation of new treatments in patients with SLE. Lupus Sci Med 2019;6:e000321. [PMID: 31321062 DOI: 10.1136/lupus-2019-000321] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
58 Souri M, Mokuda S, Inanami H, Osaki T, Takasugi K, Ichinose A. Non-autoimmune combined factor XIII A and B subunit deficiencies in rheumatoid arthritis patients treated with anti-interleukin-6 receptor monoclonal antibody (tocilizumab). Thrombosis Research 2016;140:100-5. [DOI: 10.1016/j.thromres.2016.02.026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
59 Myasoedova E. Lipids and lipid changes with synthetic and biologic disease-modifying antirheumatic drug therapy in rheumatoid arthritis: implications for cardiovascular risk. Curr Opin Rheumatol 2017;29:277-84. [PMID: 28207495 DOI: 10.1097/BOR.0000000000000378] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
60 Agca R, Heslinga SC, Rollefstad S, Heslinga M, Mcinnes IB, Peters MJL, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DPM, Nurmohamed MT. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2016;76:17-28. [DOI: 10.1136/annrheumdis-2016-209775] [Cited by in Crossref: 512] [Cited by in F6Publishing: 371] [Article Influence: 102.4] [Reference Citation Analysis]
61 Taylor PC, Kremer JM, Emery P, Zuckerman SH, Ruotolo G, Zhong J, Chen L, Witt S, Saifan C, Kurzawa M, Otvos JD, Connelly MA, Macias WL, Schlichting DE, Rooney TP, de Bono S, McInnes IB. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Ann Rheum Dis 2018;77:988-95. [PMID: 29463520 DOI: 10.1136/annrheumdis-2017-212461] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
62 Pope JE, Choy EH. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Semin Arthritis Rheum 2021;51:219-29. [PMID: 33385862 DOI: 10.1016/j.semarthrit.2020.11.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
63 Mcinnes IB, Buckley CD, Isaacs JD. Cytokines in rheumatoid arthritis — shaping the immunological landscape. Nat Rev Rheumatol 2016;12:63-8. [DOI: 10.1038/nrrheum.2015.171] [Cited by in Crossref: 224] [Cited by in F6Publishing: 196] [Article Influence: 37.3] [Reference Citation Analysis]
64 Welsh P, Grassia G, Botha S, Sattar N, Maffia P. Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? Br J Pharmacol 2017;174:3898-913. [PMID: 28409825 DOI: 10.1111/bph.13818] [Cited by in Crossref: 90] [Cited by in F6Publishing: 72] [Article Influence: 22.5] [Reference Citation Analysis]
65 Kremer JM, Genovese MC, Keystone E, Taylor PC, Zuckerman SH, Ruotolo G, Schlichting DE, Crotzer VL, Nantz E, Beattie SD, Macias WL. Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis. Arthritis & Rheumatology 2017;69:943-52. [DOI: 10.1002/art.40036] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
66 Reyes-Soffer G, Westerterp M. Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation. Pharmacol Res 2021;169:105689. [PMID: 34033878 DOI: 10.1016/j.phrs.2021.105689] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Chen DY, Chen YM, Hsieh TY, Hsieh CW, Lin CC, Lan JL. Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17:52. [PMID: 25889426 DOI: 10.1186/s13075-015-0559-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
68 Fragoulis GE, Soulaidopoulos S, Sfikakis PP, Dimitroulas T, D Kitas G. Effect of Biologics on Cardiovascular Inflammation: Mechanistic Insights and Risk Reduction. J Inflamm Res 2021;14:1915-31. [PMID: 34017189 DOI: 10.2147/JIR.S282691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Balogh E, Pusztai A, Hamar A, Végh E, Szamosi S, Kerekes G, Mccormick J, Biniecka M, Szántó S, Szűcs G, Nagy Z, Fearon U, Veale DJ, Szekanecz Z. Autoimmune and angiogenic biomarkers in autoimmune atherosclerosis. Clinical Immunology 2019;199:47-51. [DOI: 10.1016/j.clim.2018.12.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
70 Alten R, Mischkewitz M, Stefanski A, Dörner T. Januskinase-Inhibitoren: State of the Art im klinischen Einsatz und Zukunftsperspektiven. Z Rheumatol 2020;79:241-54. [DOI: 10.1007/s00393-020-00768-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
71 Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe DJ, Bombardier C. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. Cochrane Database Syst Rev 2016;:CD010227. [PMID: 27571502 DOI: 10.1002/14651858.CD010227.pub2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 5.2] [Reference Citation Analysis]
72 Cacciapaglia F, Anelli MG, Rinaldi A, Fornaro M, Lopalco G, Scioscia C, Lapadula G, Iannone F. Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment. Mediators Inflamm 2018;2018:2453265. [PMID: 30405318 DOI: 10.1155/2018/2453265] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
73 Giollo A, Bissell LA, Buch MH. Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review. Expert Opin Drug Saf 2018;17:697-708. [PMID: 29871535 DOI: 10.1080/14740338.2018.1483331] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
74 Ikonomidis I, Pavlidis G, Katsimbri P, Lambadiari V, Parissis J, Andreadou I, Tsoumani M, Boumpas D, Kouretas D, Iliodromitis E. Tocilizumab improves oxidative stress and endothelial glycocalyx: A mechanism that may explain the effects of biological treatment on COVID-19. Food Chem Toxicol 2020;145:111694. [PMID: 32822775 DOI: 10.1016/j.fct.2020.111694] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
75 Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Devel Ther 2017;11:1593-603. [PMID: 28579757 DOI: 10.2147/DDDT.S100302] [Cited by in Crossref: 46] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
76 DeMizio DJ, Geraldino-Pardilla LB. Autoimmunity and Inflammation Link to Cardiovascular Disease Risk in Rheumatoid Arthritis. Rheumatol Ther 2020;7:19-33. [PMID: 31853784 DOI: 10.1007/s40744-019-00189-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
77 Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) 2014;53:2143-54. [PMID: 24907149 DOI: 10.1093/rheumatology/keu224] [Cited by in Crossref: 163] [Cited by in F6Publishing: 137] [Article Influence: 23.3] [Reference Citation Analysis]
78 Ferretti G, Bacchetti T, Johnston TP, Banach M, Pirro M, Sahebkar A. Lipoprotein(a): A missing culprit in the management of athero-thrombosis? J Cell Physiol 2018;233:2966-81. [DOI: 10.1002/jcp.26050] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
79 Müller N, Schulte DM, Türk K, Freitag-Wolf S, Hampe J, Zeuner R, Schröder JO, Gouni-Berthold I, Berthold HK, Krone W, Rose-John S, Schreiber S, Laudes M. IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J Lipid Res 2015;56:1034-42. [PMID: 25713100 DOI: 10.1194/jlr.P052209] [Cited by in Crossref: 66] [Cited by in F6Publishing: 31] [Article Influence: 11.0] [Reference Citation Analysis]
80 Serhal M, Longenecker CT. Preventing Heart Failure in Inflammatory and Immune Disorders. Curr Cardiovasc Risk Rep 2014;8:392. [PMID: 26316924 DOI: 10.1007/s12170-014-0392-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
81 Fragoulis GE, Panayotidis I, Nikiphorou E. Cardiovascular Risk in Rheumatoid Arthritis and Mechanistic Links: From Pathophysiology to Treatment. Curr Vasc Pharmacol 2020;18:431-46. [PMID: 31258091 DOI: 10.2174/1570161117666190619143842] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
82 Van Raemdonck K, Umar S, Szekanecz Z, Zomorrodi RK, Shahrara S. Impact of obesity on autoimmune arthritis and its cardiovascular complications. Autoimmunity Reviews 2018;17:821-35. [DOI: 10.1016/j.autrev.2018.02.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
83 Lee JS, Chapman MJ, Piraino P, Lamerz J, Schindler T, Cutler P, Dernick G. Remodeling of plasma lipoproteins in patients with rheumatoid arthritis: Interleukin-6 receptor-alpha inhibition with tocilizumab. Proteomics Clin Appl 2016;10:183-94. [PMID: 26201085 DOI: 10.1002/prca.201500036] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
84 Renshall L, Arnold N, West L, Braithwaite A, Pickworth J, Walker R, Alfaidi M, Chamberlain J, Casbolt H, Thompson AAR, Holt C, Iglarz M, Francis S, Lawrie A. Selective improvement of pulmonary arterial hypertension with a dual ETA/ETB receptors antagonist in the apolipoprotein E-/- model of PAH and atherosclerosis. Pulm Circ 2018;8:2045893217752328. [PMID: 29261014 DOI: 10.1177/2045893217752328] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
85 Toussirot E, Marotte H, Mulleman D, Cormier G, Coury F, Gaudin P, Dernis E, Bonnet C, Damade R, Grauer JL, Abdesselam TA, Guillibert-Karras C, Lioté F, Hilliquin P, Sacchi A, Wendling D, Le Goff B, Puyraveau M, Dumoulin G. Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study. Arthritis Res Ther 2020;22:224. [PMID: 32993784 DOI: 10.1186/s13075-020-02297-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
86 Adorni MP, Ronda N, Bernini F, Zimetti F. High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives. Cells 2021;10:574. [PMID: 33807918 DOI: 10.3390/cells10030574] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
87 Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018;15:505-522. [PMID: 30065258 DOI: 10.1038/s41569-018-0064-2] [Cited by in Crossref: 552] [Cited by in F6Publishing: 444] [Article Influence: 276.0] [Reference Citation Analysis]
88 Reddel CJ, Allen JD, Ehteda A, Taylor R, Chen VM, Curnow JL, Kritharides L, Robertson G. Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent. J Thromb Haemost 2017;15:477-86. [PMID: 28058802 DOI: 10.1111/jth.13612] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
89 Tornero Molina J, Balsa Criado A, Blanco García F, Blanco Alonso R, Bustabad S, Calvo Alen J, Corominas H, Fernández Nebro A, Román Ivorra JA, Sanmartí R. Expert Recommendations on the Interleukin 6 Blockade in Patients with Rheumatoid Arthritis. Reumatol Clin (Engl Ed) 2020;16:272-81. [PMID: 30098882 DOI: 10.1016/j.reuma.2018.07.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
90 Weinblatt ME, Mease P, Mysler E, Takeuchi T, Drescher E, Berman A, Xing J, Zilberstein M, Banerjee S, Emery P. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Arthritis Rheumatol 2015;67:2591-600. [PMID: 26138593 DOI: 10.1002/art.39249] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 10.0] [Reference Citation Analysis]
91 Monemi S, Berber E, Sarsour K, Wang J, Lampl K, Bharucha K, Pethoe-Schramm A. Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data Sources. Rheumatol Ther 2016;3:337-52. [PMID: 27747579 DOI: 10.1007/s40744-016-0037-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
92 Connelly MA, Shimizu C, Winegar DA, Shalaurova I, Pourfarzib R, Otvos JD, Kanegaye JT, Tremoulet AH, Burns JC. Differences in GlycA and lipoprotein particle parameters may help distinguish acute kawasaki disease from other febrile illnesses in children. BMC Pediatr 2016;16:151. [PMID: 27596163 DOI: 10.1186/s12887-016-0688-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
93 Hill JA, Menon MP, Dhanireddy S, Wurfel MM, Green M, Jain R, Chan JD, Huang J, Bethune D, Turtle C, Johnston C, Xie H, Leisenring WM, Nina Kim H, Cheng GS. Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety. J Med Virol 2021;93:2270-80. [PMID: 33200828 DOI: 10.1002/jmv.26674] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
94 Tanaka T, Hishitani Y, Ogata A. Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. Biologics 2014;8:141-53. [PMID: 24741293 DOI: 10.2147/BTT.S37509] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
95 Giles JT, Wasko MCM, Chung CP, Szklo M, Blumenthal RS, Kao A, Bokhari S, Zartoshti A, Stein CM, Bathon JM. Exploring the Lipid Paradox Theory in Rheumatoid Arthritis: Associations of Low Circulating Low-Density Lipoprotein Concentration With Subclinical Coronary Atherosclerosis. Arthritis Rheumatol 2019;71:1426-36. [PMID: 30883031 DOI: 10.1002/art.40889] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
96 van Capelleveen JC, van der Valk FM, Stroes ES. Current therapies for lowering lipoprotein (a). J Lipid Res 2016;57:1612-8. [PMID: 26637277 DOI: 10.1194/jlr.R053066] [Cited by in Crossref: 51] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
97 Venetsanopoulou AI, Pelechas E, Voulgari PV, Drosos AA. The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk. Rheumatol Int 2020;40:1181-91. [DOI: 10.1007/s00296-020-04616-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
98 Singh JA, Hossain A, Mudano AS, Tanjong Ghogomu E, Suarez-Almazor ME, Buchbinder R, Maxwell LJ, Tugwell P, Wells GA. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Cochrane Database Syst Rev 2017;5:CD012657. [PMID: 28481462 DOI: 10.1002/14651858.CD012657] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
99 Singh JA, Hossain A, Tanjong Ghogomu E, Kotb A, Christensen R, Mudano AS, Maxwell LJ, Shah NP, Tugwell P, Wells GA. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2016;CD012183. [PMID: 27175934 DOI: 10.1002/14651858.cd012183] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
100 Pierini FS, Botta E, Soriano ER, Martin M, Boero L, Meroño T, Saez MS, Lozano Chiappe E, Cerda O, Citera G, Gandino I, Rosa J, Sorroche P, Kontush A, Brites F. Effect of Tocilizumab on LDL and HDL Characteristics in Patients with Rheumatoid Arthritis. An Observational Study. Rheumatol Ther 2021;8:803-15. [PMID: 33811316 DOI: 10.1007/s40744-021-00304-0] [Reference Citation Analysis]
101 Drakopoulou M, Soulaidopoulos S, Oikonomou G, Tousoulis D, Toutouzas K. Cardiovascular Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Curr Vasc Pharmacol 2020;18:488-506. [PMID: 32056527 DOI: 10.2174/1570161118666200214115532] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
102 McMahon M, Skaggs B. Pathogenesis and treatment of atherosclerosis in lupus. Rheum Dis Clin North Am 2014;40:475-95, viii. [PMID: 25034157 DOI: 10.1016/j.rdc.2014.04.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
103 Rigby WFC, Lampl K, Low JM, Furst DE. Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs. Int J Rheumatol 2017;2017:9614241. [PMID: 29225625 DOI: 10.1155/2017/9614241] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
104 Bergström U, Jovinge S, Persson J, Jacobsson LTH, Turesson C. Effects of Treatment with Adalimumab on Blood Lipid Levels and Atherosclerosis in Patients with Rheumatoid Arthritis. Curr Ther Res Clin Exp 2018;89:1-6. [PMID: 30128057 DOI: 10.1016/j.curtheres.2018.07.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
105 Makrilakis K, Fragiadaki K, Smith J, Sfikakis PP, Kitas GD. Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade. Clin Rheumatol. 2015;34:419-427. [PMID: 24912961 DOI: 10.1007/s10067-014-2704-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
106 Kang EH, Liao KP, Kim SC. Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis. Curr Rheumatol Rep 2018;20. [DOI: 10.1007/s11926-018-0752-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
107 Kerrigan SA, Mcinnes IB. Reflections on ‘older’ drugs: learning new lessons in rheumatology. Nat Rev Rheumatol 2020;16:179-83. [DOI: 10.1038/s41584-020-0375-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
108 Favalli EG, Matucci-Cerinic M, Szekanecz Z. The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis. Autoimmun Rev 2020;19:102421. [PMID: 31733368 DOI: 10.1016/j.autrev.2019.102421] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
109 Gualtierotti R. Understanding cardiovascular risk in rheumatoid arthritis: Still a long way to go. Atherosclerosis 2017;256:123-4. [PMID: 27993384 DOI: 10.1016/j.atherosclerosis.2016.11.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
110 Karpouzas GA, Bui VL, Ronda N, Hollan I, Ormseth SR. Biologics and atherosclerotic cardiovascular risk in rheumatoid arthritis: a review of evidence and mechanistic insights. Expert Rev Clin Immunol 2021;17:355-74. [PMID: 33673792 DOI: 10.1080/1744666X.2021.1899809] [Reference Citation Analysis]
111 Lazzerini PE, Capecchi PL, Guidelli GM, Selvi E, Acampa M, Laghi-Pasini F. Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date. Drug Des Devel Ther 2016;10:3083-98. [PMID: 27713619 DOI: 10.2147/DDDT.S99898] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
112 Ellis KL, Boffa MB, Sahebkar A, Koschinsky ML, Watts GF. The renaissance of lipoprotein(a): Brave new world for preventive cardiology? Progress in Lipid Research 2017;68:57-82. [DOI: 10.1016/j.plipres.2017.09.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
113 Tournadre A, Mathieu S, Soubrier M. Managing cardiovascular risk in patients with inflammatory arthritis: practical considerations. Ther Adv Musculoskelet Dis 2016;8:180-91. [PMID: 27721904 DOI: 10.1177/1759720X16664306] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
114 Zanoli L, Briet M, Empana JP, Cunha PG, Mäki-Petäjä KM, Protogerou AD, Tedgui A, Touyz RM, Schiffrin EL, Spronck B, Bouchard P, Vlachopoulos C, Bruno RM, Boutouyrie P; Association for Research into Arterial Structure, Physiology (ARTERY) Society, the European Society of Hypertension (ESH) Working Group on Vascular Structure and Function, and the European Network for Noninvasive Investigation of Large Arteries. Vascular consequences of inflammation: a position statement from the ESH Working Group on Vascular Structure and Function and the ARTERY Society. J Hypertens 2020;38:1682-98. [PMID: 32649623 DOI: 10.1097/HJH.0000000000002508] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 26.0] [Reference Citation Analysis]
115 Desjardins MP, Sidibé A, Fortier C, Mac-Way F, De Serres S, Larivière R, Spronck B, Goupil R, Agharazii M. Impact of kidney transplantation on aortic stiffness and aortic stiffness index β0. J Hypertens 2019;37:1521-8. [PMID: 30747794 DOI: 10.1097/HJH.0000000000002058] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
116 Soysal P, Arik F, Smith L, Jackson SE, Isik AT. Inflammation, Frailty and Cardiovascular Disease. Adv Exp Med Biol 2020;1216:55-64. [PMID: 31894547 DOI: 10.1007/978-3-030-33330-0_7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 28.0] [Reference Citation Analysis]
117 AbouAssi H, Connelly MA, Bateman LA, Tune KN, Huebner JL, Kraus VB, Winegar DA, Otvos JD, Kraus WE, Huffman KM. Does a lack of physical activity explain the rheumatoid arthritis lipid profile? Lipids Health Dis 2017;16:39. [PMID: 28187765 DOI: 10.1186/s12944-017-0427-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
118 Ma J, Chen X. Anti-inflammatory Therapy for Coronary Atherosclerotic Heart Disease: Unanswered Questions Behind Existing Successes. Front Cardiovasc Med 2020;7:631398. [PMID: 33598482 DOI: 10.3389/fcvm.2020.631398] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
119 Ellis KL, Chakraborty A, Moses EK, Watts GF. To test, or not to test: that is the question for the future of lipoprotein(a). Expert Rev Cardiovasc Ther 2019;17:241-50. [PMID: 30916582 DOI: 10.1080/14779072.2019.1596799] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
120 Zeng F, Li S, Yang G, Luo Y, Qi T, Liang Y, Yang T, Zhang L, Wang R, Zhu L, Li H, Xu X. Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis. Acta Pharm Sin B 2020. [PMID: 33078092 DOI: 10.1016/j.apsb.2020.10.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Singh JA, Hossain A, Tanjong Ghogomu E, Mudano AS, Tugwell P, Wells GA. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). Cochrane Database Syst Rev 2016;11:CD012437. [PMID: 27855242 DOI: 10.1002/14651858.CD012437] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
122 Kahl L, Patel J, Layton M, Binks M, Hicks K, Leon G, Hachulla E, Machado D, Staumont-Sallé D, Dickson M, Condreay L, Schifano L, Zamuner S, van Vollenhoven RF; JAK115919 Study Team. Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus. Lupus 2016;25:1420-30. [PMID: 27055521 DOI: 10.1177/0961203316640910] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
123 Tang KT, Chao YH, Chen DY, Lim YP, Chen YM, Li YR, Yang DH, Lin CC. Betahistine attenuates murine collagen-induced arthritis by suppressing both inflammatory and Th17 cell responses. Int Immunopharmacol 2016;39:236-45. [PMID: 27494687 DOI: 10.1016/j.intimp.2016.07.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
124 Wang L, Zhang Y, Zhang SY. Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future. Chin Med J (Engl) 2019;132:2972-83. [PMID: 31855971 DOI: 10.1097/CM9.0000000000000530] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
125 Winau L, Nagel E, Herrmann E, Puntmann VO. Towards the Clinical Management of Cardiac Involvement in Systemic Inflammatory Conditions—a Central Role for CMR. Curr Cardiovasc Imaging Rep 2018;11. [DOI: 10.1007/s12410-018-9451-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
126 Behl T, Kaur I, Sehgal A, Zengin G, Brisc C, Brisc MC, Munteanu MA, Nistor-Cseppento DC, Bungau S. The Lipid Paradox as a Metabolic Checkpoint and Its Therapeutic Significance in Ameliorating the Associated Cardiovascular Risks in Rheumatoid Arthritis Patients. Int J Mol Sci 2020;21:E9505. [PMID: 33327502 DOI: 10.3390/ijms21249505] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol 2020;16:335-45. [PMID: 32327746 DOI: 10.1038/s41584-020-0419-z] [Cited by in Crossref: 97] [Cited by in F6Publishing: 68] [Article Influence: 97.0] [Reference Citation Analysis]
128 Chen DY, Lin CC, Chen YM, Chao YH, Yang DH. Dextromethorphan Exhibits Anti-inflammatory and Immunomodulatory Effects in a Murine Model of Collagen-Induced Arthritis and in Human Rheumatoid Arthritis. Sci Rep 2017;7:11353. [PMID: 28900117 DOI: 10.1038/s41598-017-11378-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
129 Morel J, Tournadre A, Sellam J, Bouhnik Y, Cornec D, Devauchelle-Pensec V, Dieudé P, Goupille P, Kluger N, Lazaro E, Le Goff B, de Lédinghen V, Lequerré T, Nocturne G, Seror R, Truchetet ME, Verhoeven F, Pham T, Richez C. Practical Management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). Joint Bone Spine 2021;88:105221. [PMID: 34183155 DOI: 10.1016/j.jbspin.2021.105221] [Reference Citation Analysis]
130 Ng ACT, Delgado V, Borlaug BA, Bax JJ. Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging. Nat Rev Cardiol 2021;18:291-304. [PMID: 33188304 DOI: 10.1038/s41569-020-00465-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
131 Singh JA, Hossain A, Tanjong Ghogomu E, Mudano AS, Maxwell LJ, Buchbinder R, Lopez-Olivo MA, Suarez-Almazor ME, Tugwell P, Wells GA. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. Cochrane Database Syst Rev 2017;3:CD012591. [PMID: 28282491 DOI: 10.1002/14651858.CD012591] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
132 Szekanecz Z, Kerekes G, Végh E, Kardos Z, Baráth Z, Tamási L, Shoenfeld Y. Autoimmune atherosclerosis in 3D: How it develops, how to diagnose and what to do. Autoimmunity Reviews 2016;15:756-69. [DOI: 10.1016/j.autrev.2016.03.014] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
133 Giles JT. Rheumatoid Arthritis Pharmacotherapies: Do They Have Anti-Atherosclerotic Activity? Curr Rheumatol Rep 2016;18. [DOI: 10.1007/s11926-016-0578-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
134 Liao KP, Playford MP, Frits M, Coblyn JS, Iannaccone C, Weinblatt ME, Shadick NS, Mehta NN. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc 2015;4:e001588. [PMID: 25637346 DOI: 10.1161/JAHA.114.001588] [Cited by in Crossref: 63] [Cited by in F6Publishing: 36] [Article Influence: 10.5] [Reference Citation Analysis]
135 Dutzmann J, Daniel JM, Bauersachs J, Hilfiker-Kleiner D, Sedding DG. Emerging translational approaches to target STAT3 signalling and its impact on vascular disease. Cardiovasc Res 2015;106:365-74. [PMID: 25784694 DOI: 10.1093/cvr/cvv103] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 8.7] [Reference Citation Analysis]
136 Moriya J. Critical roles of inflammation in atherosclerosis. Journal of Cardiology 2019;73:22-7. [DOI: 10.1016/j.jjcc.2018.05.010] [Cited by in Crossref: 82] [Cited by in F6Publishing: 58] [Article Influence: 41.0] [Reference Citation Analysis]
137 Poller WC, Berger A, Dreger H, Morgera S, Enke-melzer K. Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2-year follow-up of a prospective single center study. Atherosclerosis Supplements 2017;30:174-9. [DOI: 10.1016/j.atherosclerosissup.2017.05.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
138 Cai T, Zhang Y, Ho YL, Link N, Sun J, Huang J, Cai TA, Damrauer S, Ahuja Y, Honerlaw J, Huang J, Costa L, Schubert P, Hong C, Gagnon D, Sun YV, Gaziano JM, Wilson P, Cho K, Tsao P, O'Donnell CJ, Liao KP; VA Million Veteran Program. Association of Interleukin 6 Receptor Variant With Cardiovascular Disease Effects of Interleukin 6 Receptor Blocking Therapy: A Phenome-Wide Association Study. JAMA Cardiol 2018;3:849-57. [PMID: 30090940 DOI: 10.1001/jamacardio.2018.2287] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 22.0] [Reference Citation Analysis]
139 Charles-Schoeman C, DeMasi R, Valdez H, Soma K, Hwang LJ, Boy MG, Biswas P, McInnes IB. Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis. Arthritis Rheumatol 2019;71:1450-9. [PMID: 31385441 DOI: 10.1002/art.40911] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
140 Gabay C, McInnes IB, Kavanaugh A, Tuckwell K, Klearman M, Pulley J, Sattar N. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1806-12. [PMID: 26613768 DOI: 10.1136/annrheumdis-2015-207872] [Cited by in Crossref: 80] [Cited by in F6Publishing: 70] [Article Influence: 13.3] [Reference Citation Analysis]
141 Welsh P, Tuckwell K, McInnes IB, Sattar N. Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis. Atherosclerosis 2016;254:167-71. [PMID: 27744141 DOI: 10.1016/j.atherosclerosis.2016.10.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
142 Bag-Ozbek A, Giles JT. Inflammation, adiposity, and atherogenic dyslipidemia in rheumatoid arthritis: is there a paradoxical relationship? Curr Allergy Asthma Rep 2015;15:497. [PMID: 25504261 DOI: 10.1007/s11882-014-0497-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
143 Cañete JD, Hernández MV, Sanmartí R. Safety profile of biological therapies for treating rheumatoid arthritis. Expert Opinion on Biological Therapy 2017;17:1089-103. [DOI: 10.1080/14712598.2017.1346078] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
144 Vanhoutte F, Mazur M, Voloshyn O, Stanislavchuk M, Van der Aa A, Namour F, Galien R, Meuleners L, van 't Klooster G. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials. Arthritis Rheumatol 2017;69:1949-59. [PMID: 28622463 DOI: 10.1002/art.40186] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 11.5] [Reference Citation Analysis]
145 Ursini F, Ruscitti P, Caio GPI, Manfredini R, Giacomelli R, De Giorgio R. The effect of non-TNF-targeted biologics on vascular dysfunction in rheumatoid arthritis: A systematic literature review. Autoimmunity Reviews 2019;18:501-9. [DOI: 10.1016/j.autrev.2019.03.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
146 Iqbal F, Baker WS, Khan MI, Thukuntla S, McKinney KH, Abate N, Tuvdendorj D. Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism. Br J Pharmacol 2017;174:3986-4006. [PMID: 28326542 DOI: 10.1111/bph.13743] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
147 Montecucco F, Favari E, Norata GD, Ronda N, Nofer JR, Vuilleumier N. Impact of systemic inflammation and autoimmune diseases on apoA-I and HDL plasma levels and functions. Handb Exp Pharmacol 2015;224:455-82. [PMID: 25522998 DOI: 10.1007/978-3-319-09665-0_14] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
148 Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I, Boy M, Geier J, Luo Z, Zuckerman A, Riese R. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Semin Arthritis Rheum 2016;46:71-80. [PMID: 27079757 DOI: 10.1016/j.semarthrit.2016.03.004] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 10.2] [Reference Citation Analysis]
149 Soubrier M, Pei J, Durand F, Gullestad L, John A. Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis. Rheumatol Ther 2017;4:133-49. [PMID: 27900570 DOI: 10.1007/s40744-016-0049-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
150 Tuñón J, Badimón L, Bochaton-Piallat ML, Cariou B, Daemen MJ, Egido J, Evans PC, Hoefer IE, Ketelhuth DFJ, Lutgens E, Matter CM, Monaco C, Steffens S, Stroes E, Vindis C, Weber C, Bäck M. Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. Cardiovasc Res 2019;115:10-9. [PMID: 30534957 DOI: 10.1093/cvr/cvy293] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 30.0] [Reference Citation Analysis]
151 Lim DT, Cannella AC, Michaud KD, Mikuls TR. Cardiovascular risk and the use of biologic agents in rheumatoid arthritis. Curr Rheumatol Rep. 2014;16:459. [PMID: 25315196 DOI: 10.1007/s11926-014-0459-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
152 Kraakman MJ, Dragoljevic D, Kammoun HL, Murphy AJ. Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis. Clin Transl Immunology 2016;5:e84. [PMID: 27350883 DOI: 10.1038/cti.2016.31] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
153 Bartoloni E, Alunno A, Valentini V, Luccioli F, Valentini E, La Paglia GMC, Leone MC, Cafaro G, Marcucci E, Gerli R. Targeting Inflammation to Prevent Cardiovascular Disease in Chronic Rheumatic Diseases: Myth or Reality? Front Cardiovasc Med 2018;5:177. [PMID: 30619884 DOI: 10.3389/fcvm.2018.00177] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
154 Ikonomidis I, Pavlidis G, Katsimbri P, Andreadou I, Triantafyllidi H, Tsoumani M, Varoudi M, Vlastos D, Makavos G, Kostelli G, Βenas D, Lekakis J, Parissis J, Boumpas D, Alexopoulos D, Iliodromitis E. Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function. Clin Res Cardiol 2019;108:1093-101. [PMID: 30859382 DOI: 10.1007/s00392-019-01443-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
155 Kilcher G, Hummel N, Didden EM, Egger M, Reichenbach S; for the GetReal Work Package 4. Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries. Rheumatology 2018;57:354-69. [DOI: 10.1093/rheumatology/kex394] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
156 Matsumoto Y, Sugioka Y, Tada M, Okano T, Mamoto K, Inui K, Habu D, Koike T. Change in skeletal muscle mass is associated with lipid profiles in female rheumatoid arthritis patients -TOMORROW study. Clin Nutr 2021;40:4500-6. [PMID: 33413913 DOI: 10.1016/j.clnu.2020.12.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
157 Kerola AM, Rollefstad S, Semb AG. Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment. Eur Cardiol 2021;16:e18. [PMID: 34040652 DOI: 10.15420/ecr.2020.44] [Reference Citation Analysis]
158 Metz AK, Diaz JA, Obi AT, Wakefield TW, Myers DD, Henke PK. Venous Thrombosis and Post-Thrombotic Syndrome: From Novel Biomarkers to Biology. Methodist Debakey Cardiovasc J 2018;14:173-81. [PMID: 30410646 DOI: 10.14797/mdcj-14-3-173] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
159 Zhu Y, Xian X, Wang Z, Bi Y, Chen Q, Han X, Tang D, Chen R. Research Progress on the Relationship between Atherosclerosis and Inflammation. Biomolecules. 2018;8. [PMID: 30142970 DOI: 10.3390/biom8030080] [Cited by in Crossref: 83] [Cited by in F6Publishing: 70] [Article Influence: 27.7] [Reference Citation Analysis]
160 Sanmartí R, Ruiz-Esquide V, Bastida C, Soy D. Tocilizumab in the treatment of adult rheumatoid arthritis. Immunotherapy 2018;10:447-64. [PMID: 29495891 DOI: 10.2217/imt-2017-0173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
161 Martínez-Hervás S, González-Navarro H. Anti-inflammatory Therapies for Cardiovascular Disease: Signaling Pathways and Mechanisms. Rev Esp Cardiol (Engl Ed) 2019;72:767-73. [PMID: 31155366 DOI: 10.1016/j.rec.2019.03.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
162 Marchio P, Guerra-Ojeda S, Vila JM, Aldasoro M, Victor VM, Mauricio MD. Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation. Oxid Med Cell Longev 2019;2019:8563845. [PMID: 31354915 DOI: 10.1155/2019/8563845] [Cited by in Crossref: 118] [Cited by in F6Publishing: 86] [Article Influence: 59.0] [Reference Citation Analysis]